CYP cynata therapeutics limited

Ann: Investor Webinar Presentation, page-9

  1. 1,039 Posts.
    lightbulb Created with Sketch. 405
    The DFU information was released with the CR presentation back in April (slides 17-19): https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02652273-7NSCRSUGSJJKGVONAOHJ1S31OE/pdf?access_token=0007YUZeQM9jdt0x5ryaOwTUcoAr

    What is notable is the inclusion of more preclinical data demonstrating Cymerus MSCs reduction of heterogeneity compared to tissue-derived MSCs. Heterogeneity is a major hurdle to the commercialisation of MSC therapies. As the FDA noted in the ODAC briefing document for Rem-L, in the absence of outstanding results from a well-controlled clinical trial, the therapy at the very least needs to have a mechanism of action (MOA) consistent with what is observed in laboratory testing. If the underlying treatment is not consistent on a batch-to-batch basis, that makes it difficult to achieve. Fortunately, a single blood donation is the foundation for 21 million clinical doses of Cymerus MSCs, greatly improving the probability that the clinical MOA will closely match what is expected.
    Last edited by truss20: 20/09/23
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
-0.005(2.86%)
Mkt cap ! $38.41M
Open High Low Value Volume
17.5¢ 17.5¢ 17.0¢ $42.82K 247.5K

Buyers (Bids)

No. Vol. Price($)
4 141820 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 58088 1
View Market Depth
Last trade - 14.00pm 07/08/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.